Parexel releases mostly heartening statistics about the industry, tabulated as of late 2008. more...

Reflections on today’s podcast—excerpts from a speech by Roy Vagelos, who lead Merck during the late 1980s and 1990s. more...

A research scandal at a Tufts facility shows that peer review cannot identify scientific fraud quickly. more...

Thoughts on the numerical implications of the impending mega mergers between Pfizer-Wyeth and Merck-Schering-Plough. more...

Reflections on the new year and what pharma should do to avoid a pounding from politicians. more...

To avoid lawsuits, train employees to pretend a lawyer is reading every email, text message and Microsoft Word document. more...

Despite a cancelled FDA pilot project, CDISC leaders explain why the ODM data standard still matters. more...

With ISO certification, a California firm tries to lower regulatory risks inherent in translation by ensuring high quality—and avoiding mistakes. more...

Thoughts on recent sponsor news: GSK cuts hundreds of R&D jobs and Pfizer abandons cardiovascular disease. more...

Reflections on a certain Situation and what may be a not uncommon predicament. more...

The debut of our list of suites—integrated technology firms or services firms providing at least three major types of research systems. more...

Using genomic expertise, the Almac Group starts a search for its own compounds. more...

In Side Effects, reporter Alison Bass delves into the New York Attorney General’s 2004 case against GlaxoSmithKline. more...

The SAFE-Biopharma Association is hoping to nudge the pharmaceutical industry toward a single electronic signature standard. more...

Does Windows have something to contribute to the clinical trial arena? Microsoft asserts its platform is more open and robust. more...

What to count (or not), and why. more...